These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 34376537)
1. Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming. Simonetta F; Lohmeyer JK; Hirai T; Maas-Bauer K; Alvarez M; Wenokur AS; Baker J; Aalipour A; Ji X; Haile S; Mackall CL; Negrin RS Clin Cancer Res; 2021 Nov; 27(21):6054-6064. PubMed ID: 34376537 [TBL] [Abstract][Full Text] [Related]
2. Harnessing Chimeric Antigen Receptor-engineered Invariant Natural Killer T Cells: Therapeutic Strategies for Cancer and the Tumor Microenvironment. Wang Y; Li YR Curr Pharm Biotechnol; 2024; 25(15):2001-2011. PubMed ID: 38310449 [TBL] [Abstract][Full Text] [Related]
3. Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Li YR; Zhou Y; Kim YJ; Zhu Y; Ma F; Yu J; Wang YC; Chen X; Li Z; Zeng S; Wang X; Lee D; Ku J; Tsao T; Hardoy C; Huang J; Cheng D; Montel-Hagen A; Seet CS; Crooks GM; Larson SM; Sasine JP; Wang X; Pellegrini M; Ribas A; Kohn DB; Witte O; Wang P; Yang L Cell Rep Med; 2021 Nov; 2(11):100449. PubMed ID: 34841295 [TBL] [Abstract][Full Text] [Related]
4. Traversing the bench to bedside journey for iNKT cell therapies. O'Neal J; Mavers M; Jayasinghe RG; DiPersio JF Front Immunol; 2024; 15():1436968. PubMed ID: 39170618 [TBL] [Abstract][Full Text] [Related]
5. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy. Li YR; Zhou Y; Yu J; Zhu Y; Lee D; Zhu E; Li Z; Kim YJ; Zhou K; Fang Y; Lyu Z; Chen Y; Tian Y; Huang J; Cen X; Husman T; Cho JM; Hsiai T; Zhou JJ; Wang P; Puliafito BR; Larson SM; Yang L Mol Ther; 2024 Jun; 32(6):1849-1874. PubMed ID: 38584391 [TBL] [Abstract][Full Text] [Related]
6. Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review. Tang C; Zhang Y Pathol Res Pract; 2024 Oct; 262():155518. PubMed ID: 39146830 [TBL] [Abstract][Full Text] [Related]
7. PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity. Moraes Ribeiro E; Secker KA; Nitulescu AM; Schairer R; Keppeler H; Wesle A; Schmid H; Schmitt A; Neuber B; Chmiest D; Podavini S; Märklin M; Klimovich B; Schmitt M; Korkmaz F; Lengerke C; Schneidawind C; Schneidawind D J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38296597 [TBL] [Abstract][Full Text] [Related]
8. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation. Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510 [TBL] [Abstract][Full Text] [Related]
9. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256 [TBL] [Abstract][Full Text] [Related]
10. Comparative assessment of autologous and allogeneic iNKT cell transfer in iNKT cell-based immunotherapy. Takami M; Motohashi S Front Immunol; 2024; 15():1457771. PubMed ID: 39224603 [TBL] [Abstract][Full Text] [Related]
11. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer. Marcus A; Eshhar Z Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086 [TBL] [Abstract][Full Text] [Related]
12. [Development of allogeneic CAR T-cells]. Alcazer V; Depil S Bull Cancer; 2021 Oct; 108(10S):S73-S80. PubMed ID: 34920810 [TBL] [Abstract][Full Text] [Related]